Abstract:Background-Phosphodiesterase type 5 (PDE5) inhibition has been shown to exert profound beneficial effects in the failing heart, suggesting a significant role for PDE5 in the development of congestive heart failure (CHF). The purpose of this study is to test the hypothesis that oxidative stress causes increased PDE5 expression in cardiac myocytes and that increased PDE5 contributes to the development of CHF.Methods and Results-Myocardial PDE5 expression and cellular distribution were determined in left ventricular samples from patients with end-stage CHF and normal donors and from mice after transverse aortic constriction (TAC)-induced CHF. Compared with donor human hearts, myocardial PDE5 protein was increased approximate to 4.5-fold in CHF samples, and the increase of myocardial PDE5 expression was significantly correlated with myocardial oxidative stress markers 3'-nitrotyrosine or 4-hydroxynonenal expression (P < 0.05). Histological examination demonstrated that PDE5 was mainly expressed in vascular smooth muscle in normal donor hearts, but its expression was increased in both cardiac myocytes and vascular smooth muscle of CHF hearts. Myocardial PDE5 protein content and activity also increased in mice after TAC-induced CHF (P < 0.05). When the superoxide dismutase (SOD) mimetic M40401 was administered to attenuate oxidative stress, the increased PDE5 protein and activity caused by TAC was blunted, and the hearts were protected against left ventricular hypertrophy and CHF. Conversely, increased myocardial oxidative stress in superoxide dismutase 3 knockout mice caused a greater increase of PDE5 expression and CHF after TAC. In addition, administration of sildenafil to inhibit PDE5 attenuated TAC-induced myocardial oxidative stress, PDE5 expression, and CHF.Conclusions-Myocardial oxidative stress increases PDE5 expression in the failing heart. Reducing oxidative stress by treatment with M40401 attenuated cardiomyocyte PDE5 expression. This and selective inhibition of PDE5 protected the heart against pressure overload-induced left ventricular hypertrophy and CHF. (Circulation. 2010;121:1474-1483.)

Oxidative stress in patients with pulmonary hypertension

Pulmonary hypertension and oxidative stress: Where is the link?

Oxidative Stress and Antioxidative Therapy in Pulmonary Arterial Hypertension

Oxidative Stress and Antioxidant Therapy in Pulmonary Hypertension

Nadph Oxidase Activation Played A Critical Role in the Oxidative Stress Process in Stable Coronary Artery Disease

Prognostic Value of Oxidative Stress Markers in Patients with Pulmonary Arterial or Chronic Thromboembolic Pulmonary Hypertension

Oxidative Stress and Its Implications in the Right Ventricular Remodeling Secondary to Pulmonary Hypertension

Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy

Oxidative stress in acute pulmonary embolism: emerging roles and therapeutic implications

Oxidative Stress and Vascular Remodeling in Pulmonary Hypertension

Redox Regulation of Ion Channels and Receptors in Pulmonary Hypertension

Oxidative Profiling of the Failing Right Heart in Rats with Pulmonary Hypertension.

Oxidative Stress and Hypertension

Exacerbated Pulmonary Arterial Hypertension and Right Ventricular Hypertrophy in Animals with Loss of Function of Extracellular Superoxide Dismutase.

Oxidative stress as one of the pathogenetic mechanisms of hepatopulmonary syndrome in patients with liver cirrhosis

Oxidative Stress in COPD: Sources, Markers, and Potential Mechanisms

Reactive oxygen species induced Ca2+ influx via TRPV4 and microvascular endothelial dysfunction in the SU5416/hypoxia model of pulmonary arterial hypertension.

Importance of oxidative stress in the evaluation of acute pulmonary embolism severity

Oxidative Stress Regulates Left Ventricular Pde5 Expression in the Failing Heart

Increased Reactive Oxygen Species Production and Functional Alterations in Antioxidant Enzymes in Human Failing Myocardium

Effect of Hydrogen Sulfide on Oxidative Stress in Hypoxic Pulmonary Hypertension